Risperdal Lawsuits

The world’s second biggest maker of medical products, Johnson & Johnson’s Risperdal schizophrenia drug has annual global sales of $2.1 billion. While a J&J spokesperson claimed “an update to the Risperdal label is indeed being made, and we will be sending out letters to health care professionals soon,” the company had already issued Risperdal warning letters to Canadian doctors and pharmacists six months before announcing Risperdal side effect risks in the U.S.
Clinical trials testing Risperdal in Alzheimer patients heightened concerns that the occurrence of serious Risperdal side effects is higher than previously thought. Among 764 Risperdal patients, 29 cases of stroke and stroke-related events were seen, in addition to four deaths. A Public Citizen consumer watchdog group pharmacist and research analyst thinks that the recent Risperdal studies should push U.S. regulators to deeper examine if younger aged schizophrenia patients are also more prone to experiencing Risperdal stroke and other side effects of Risperdal.
Risperdal uses upon approval only included schizophrenia treatment. Risperdal is often prescribed to control behavioral disorders in elderly patients with dementia and Alzheimer’s disease, including delusions, aggression, and anxiety, but the recent Risperdal stroke announcement shows there is an higher risk in prescribing Risperdal to a wider range of patients.

Links 1 2